πŸ‡ΊπŸ‡Έ FDA
Patent

US 9290541

TCL1 peptides for immunotherapy

granted A61KA61K2239/48A61K38/08

Quick answer

US patent 9290541 (TCL1 peptides for immunotherapy) held by The Board of Regents of the University of Texas System expires Mon Mar 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Mar 22 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K2239/48, A61K38/08, A61K38/10, A61K38/16